Team
ransplant
T
or
l
y
Ba
t
1984 – Firs
YEARS
of pioneering
transplants
BAYLOR AN N ETTE C. AND HAROLD C. SIMMONS
TRAN SPLANT INSTITUTE ANNUAL RE POR T
Transplant surgeons
Giuliano Testa, MD and Peter Kim, MD, on the medical
staff of Baylor University Medical Center, utilize the G9MD Broadcast Center to advance
surgical techniques and collaborate with physicians worldwide. The use of advanced
streaming technology is at the forefront of medical innovation.
L E A D E R SH I P L E TTE R
The best way
to predict the future
is to invent it.
What has kept Baylor Annette C. and Harold C. Simmons Transplant Institute at the
forefront of transplantation for 30 years? As one of the first to successfully treat organ
failure with transplants, we certainly had a vision of the potential lifesaving power
of transplant medicine. But we also had an instinctive awareness of the collaboration
at the heart of our field.
Transplantation is a science of relationships: the relationship that ties a donor to a recipient, a patient
to a team of specialists, and a referring physician to a transplant center. In every aspect of the care
we provide, we are committed to making these relationships work. With 30 years of advances in
transplantation behind us, we continue to pioneer methods to match patients with the treatment or
organ that ensures a successful outcome. We continue building trusted relationships with referring
physicians, keeping them involved in their patients’ care. And we continue forging a permanent bond
with the patients we treat, offering them a lifetime of care.
Our multi-specialty teams of renowned physicians and scientists care for thousands of patients before,
during and after transplantation, even finding effective alternative treatments for those who may not
be transplant candidates. As we have done for 30 years, we will carry on with the research, innovation
and patient-focused care that are essential to the future of transplant medicine. We consider it a
privilege to collaborate with referring physicians as we dedicate ourselves to transplant patients for life.
Sincerely,
Göran Klintmalm, MD, PhD, FACS
Chairman and Chief
Baylor Annette C. and Harold C.
Simmons Transplant Institute
Janice Whitmire, MBA
Vice President
Baylor Annette C. and Harold C.
Simmons Transplant Institute
1
Fi rst T
ranspla
n
t Surger
ion
ntat
a
pl
s
ran
r of T
the
fa
, God
l
z
r
a
t
Dr. S
y
1 LEADERSHIP LETTER
3 INTRODUCTION
4 LIVER
8 KIDNEY & PANCREAS
12 ISLET CELL
16 HEART
The original transplant pioneer,
Dr. Thomas Starzl was the inspiration
behind Baylor’s transplantation
program. Dr. Starzl performed the
first human liver transplants. In 1983,
20 LUNG
24 RESEARCH
26 OUTREACH
he made a presentation to Baylor on
his transplant team’s successes at the
University of Pittsburgh. He encouraged
Baylor to develop a transplant center,
recruited his student Dr. Göran
Klintmalm as medical director, and
brought his patient Amie Garrison
to Dallas, where she made history
as Baylor’s first transplant patient.
28 DONOR COMMUNITY
30 PUBLICATIONS
34 MEDICAL STAFF
36 BAYLOR FIRSTS
I N T R O DUCTI O N
Daring
to embrace
progress
With one of the world’s largest islet cell transplant programs,
we continue to make inroads in both allo-islet cell and auto
islet cell transplantation, providing hope for patients with type
1 diabetes and chronic pancreatitis.
In our heart transplantation program, the busiest in Texas and
the second largest in the nation, we have shortened the median
wait time for a heart transplant to as little as seven days.
In 2014, our lung transplant program welcomed a new team
of nationally respected transplant specialists and is growing
It takes courage to perform a liver transplant on a five-year-
rapidly in volume and outcomes.
old girl dying of liver failure. It’s especially courageous if
that procedure is the hospital’s first transplant. But that is
Clearly, our work at Baylor Annette C. and Harold C.
what happened in 1984 at Baylor Annette C. and Harold C.
Simmons Transplant Institute is inspired by a bold vision of
Simmons Transplant Institute. The transplant program was
our role in transplant medicine. Three decades of progress have
still in the planning stages, but little Amie Garrison would
shown the value of our approach. In moving transplantation
die without a new liver, and the nation’s only existing liver
forward, we are restoring countless lives. All the more reason
transplant center in Pittsburg simply didn’t have room.
that, like the little girl we saved 30 years ago, we look forward
So Baylor said yes. Today, Amie is a healthy 35-year-old
to a promising future.
mother. And the transplant team that took a gutsy move to
save a child’s life is now one of the largest and most renowned
multi-specialty transplant centers in the country.
For 30 years, the courage it took to perform Amie’s surgery
Transplant Institute, which includes the transplant services
of Baylor University Medical Center at Dallas and Baylor
All Saints Medical Center at Fort Worth. From day one,
JAN
has defined the Baylor Annette C. and Harold C. Simmons
2014
we have made historic progress in each area of specialization.
Frenchie
Our liver transplant program is internationally recognized as
HEART TRANSPLANT
AT AGE 61
a pioneering program in liver transplantation and anti-rejection
treatment as well as hepatitis B and C research. In addition,
our living donor liver program is among the top 10 in the
Just five months post-transplant, Carson
nation and one of only two programs in Texas.
“Frenchie” Cheramie was able to welcome
In our kidney transplant program, one-year survival rates
his namesake granddaughter, Carson
exceed the national average, and living donors are involved
Claire, into the world. “I never imagined
in one-fourth of all kidney transplants, which addresses
that I would ever be able to hold a
a critical global shortage of donated organs.
grandchild, but God had a different plan.”
3
Credit: SciePro / Science Source
LIVER
4
LIVER
More liver transplants are performed at Baylor
University Medical Center and Baylor All Saints
combined than anywhere else in Texas. With this level
of expertise, provided by one of the nation’s largest
transplant surgery teams, our center offers patients
a full slate of treatment options.
Living Donor Transplantation
One therapeutic option is a living donor liver transplant.
Liver Transplant Volumes BUMC & BAS
150
The procedure allows patients to receive a liver transplant
sooner—patients who likely would die without it, faced
120
112
120
99
with long waits on the transplant list.
110
96
90
In a living donor transplant, the entire diseased liver is
removed from the recipient and replaced with half of the
donor’s liver. In roughly a month, both donor and recipient
60
30
livers grow to near-full volume. Because the donated liver
is immediately transplanted without needing storage or
0
2010
2011
2012
2013
2014
transporting, it provides the best quality liver. The technically
Liver Transplant Outcomes percent alive at one year
demanding surgery must be performed by surgeons
experienced in the procedure. Baylor University Medical
US Nat’l Avg: 88.26%
100
Center is one of only two centers in Texas offering it and
92.9%
one of the top 10 in the nation for volumes.
Elastography: Non-invasive Liver Disease Management
60
94.6%
92.9%
81.7%
80
Thanks to new technology at Baylor University Medical
(SRTR Dec 2014)
80.2%
40
Center, some liver disease patients no longer have to endure
frequent liver needle biopsies to determine the progression of
20
their disease. A recent study at the Mayo Clinic, co-authored
by Sumeet Asrani, MD, a hepatologist now on the medical
0
2010
2011
2012
2013
2014
staff at Baylor Dallas, showed that magnetic resonance
elastography can measure and stage liver disease noninvasively. The technology allows hepatologists to determine
whether patients are getting better or worse, and whether
treatment is effective. This advanced imaging modality gives
physicians more information to better care for patents.
Soon to be FDA approved, it is available at only a few
3,841
LIVER
TRANSPLANTS*
SINCE INCEPTION
*Data is through Dec 2014
medical centers nationwide, Baylor among them.
5
M EET
GILBERT
GILBERT GONZALES | Age 63 | Liver Transplant
Except for being a mail carrier, Gilbert Gonzales didn’t exercise much. But a new liver changed that. Now he travels the globe
competing in the Transplant Games of America and the World Transplant Games. In 2009 his liver was failing due to a genetic
disease. Nine months later a liver transplant at Baylor Dallas kick-started his new life. He soon jumped into the transplant
games fearlessly, winning a bronze medal in discus at his first event in Grand Rapids, Michigan, and silver medals for discus
and high jump a year later in Durban, South Africa. Most recently, in Houston, Texas, Gilbert took home silver in discus and
bronze in long jump. Gilbert volunteers in Baylor’s Better Livers program, reassuring transplant patients that their lives will
get better. “It’s all about enjoying your second life and passing it along,” he says.
6
LIVER
Liver and Pancreas Disease Center
At the Liver and Pancreas Disease Center, patients with
Hepatologists on the medical staff of Baylor Dallas, as
liver tumors, including those with potentially cancerous
a part of the North American Consortium for the Study
liver lesions, and patients with pancreas tumors or chronic
of End-stage Liver Disease, are participating in studies
pancreatitis have access to a full spectrum of treatment
investigating risk factors for mortality in decompensated liver
options. One of the few centers in the nation dedicated to
patients (otherwise known as acute-on-chronic liver failure)
treating patients with liver and pancreas cancer, the center
in an effort to enhance clinical practices that will ultimately
coordinates each patient’s tumor management and plan
improve patient outcomes. This study is being conducted at
of care among specialists on the medical staff, many having
Baylor Dallas, Mayo Clinic, University of Pennsylvania and
more than 15 years of experience with such diseases.
Virginia Commonwealth University.
Since the program’s inception in 1998, more than 5,000
patients have received treatment.
JUN
Antibody-Mediated Rejection Symposium
In March 2013, Simmons Transplant Institute held the
first scientific conference to exchange information about
Ruben
antibody-mediated rejection (AMR) in liver transplantation.
LIVING DONOR LIVER
TRANSPLANT AT AGE 56
Assembling more than 165 liver transplant leaders, the
symposium confirmed the role of AMR in allograft survival.
A subsequent summary of the conference was published
in the March 2014 issue of the American Journal of
2013
Ruben Castillo had liver failure from
Transplantation and was authored by 16 attending
Hepatitis C he contracted from a blood
world-recognized specialists. Baylor’s leadership in the
transfusion. After waiting over a year
AMR findings came as a result of data mined from our
for a donor, Ruben and his wife Tammy
transplant biorepository of donor and recipient tissue
decided the Living Donor program was the
samples, which is the world’s largest.
best option. It was a chance for Tammy to
Clinical Studies
donate to Ruben and offer him a second
For patients with hepatocellular carcinoma (HCC),
chance at life. Now Ruben is
liver transplant often offers the best potential outcome.
flourishing and better than ever.
However, in some cases, the cancer may reoccur. Baylor’s
study on the Safety and Efficacy of Everolimus Treatment
in Liver Transplantation for Liver Cancer is investigating
the medication’s ability to reduce recurrent HCC in posttransplant patients. The study is the focus of an upcoming
mTOR Conference in Dallas.
1
ST
LIVER TRANSPLANT
PROGRAM IN THE
SOUTHWEST
7
Credit: SciePro / Science Source
KIDNEY
& PANCREAS
8
KI DNE Y
Kidney failure patients face two choices: try to live with
dialysis or receive a kidney transplant. Research has
shown that a kidney transplant should be first choice.
In fact, the ideal situation is for patients to avoid
Pathway to Kidney Transplant
dialysis altogether and go straight to kidney transplant.
To encourage the early referral of patients for living donor
This option — a preemptive kidney transplant — requires
kidney transplantation, Baylor developed the Pathway to
a living donor. We offer this advanced solution to help
Kidney Transplant, a patient education guide that demystifies
patients receive a kidney as soon as possible, because
the transplant process for both recipients and donors and
the less time spent on dialysis the better. The advantages
explains the benefits of the living donor kidney option.
of a preemptive kidney transplant with a living donor
The Pathway provides a step-by-step graphic simplifying each
are compelling.
phase of a patient’s treatment options and drives home the
Patients with living donor kidney transplants have much
point that the sooner patients receive a kidney, the better.
better survival rates and three times the life expectancy
Desensitization Program
compared to patients staying on dialysis. Without having
Dr. Bernard Fishbach, medical director of the Kidney
to wait for a deceased donor organ, they can receive their
Transplant Program, is leading the desensitization program.
kidneys faster. And the kidney itself is higher quality.
This very active program, which removes harmful antibodies
It starts working sooner and can last twice as long as
from the blood stream and reduces the risk of organ
a deceased donor kidney. Overall, a patient’s outcome
rejection, is available at only a few transplant centers
and quality of life are far superior.
in the United States.
KIDNEY
FUN
FUNCTI
CTION
ON
FUNCTION
KIDNEY
FUNCTION
30
3
0
KIDNEY
FUN
FUNCTI
CTION
ON
FUNCTION
20
2
0
%
10
1
0-1
15
5%
%
GET
READY
FOR
DIALYSIS
NOTE: It’s never too late to choose Path 2.
DIALYSIS
Kidney Pathway
This pathway includes checklists for patients with kidney
PATH 1
disease and potential donors to help guide them through the
steps to receive a kidney transplant as soon as possible.
Ideally, patients can be transplanted before starting dialysis,
PATIENT
WITH
KIDNEY
DISEASE
which will likely improve their clinical outcome and quality
PATH 2
of life. The graph and checklist provide recommendations
IDENTIFY
POTENTIAL
DONORS
GET READY
FOR KIDNEY
TRANSPLANT*
to patients once their kidney function deteriorates to 30
EVALUATION
FOR KIDNEY
TRANSPLANT*
KIDNEY
TRANSPLANT
INTERESTED
DONORS
percent to begin the educational, financial, physical and
potential donor candidate considerations early in order to
be ready for transplant by the time their kidneys reach 20
percent of function.
GET READY
TO BE A
KIDNEY
DONOR*
EVALUATION
TO BE A
KIDNEY
DONOR*
*Refer to applicable checklists
9
M EET
JOEL & LONNIE
JOEL & LONNIE HENDERSON | Ages 31 & 58 | Kidney Transplant
Joel Henderson’s father Lonnie seemed healthy and was enjoying life in his fifties despite his type 1 diabetes. But then came
the fainting spells at work, and Lonnie learned his kidneys were failing. That’s when Joel offered to donate a kidney to his
dad. “We were trying to give him a kidney before he would have to go on dialysis,” says Joel. After the transplant surgery,
Joel says he recovered quickly. As for Lonnie, his transplanted kidney started working within 30 minutes, he’s had no signs
of rejection, and his energy and stamina are fully restored. Joel says, “People say it was heroic, but I’m blessed to have the
opportunity. I’m just glad to have him around longer.”
10
KI DNE Y
Kidney-Pancreas Transplant
3,867
For patients with type 1 diabetes, a pancreas transplant can be
the best option. Sometimes the pancreas is transplanted alone,
but more often the pancreas and kidney are transplanted
together. Patients on the Baylor kidney-pancreas transplant
KIDNEY TRANSPLANTS
list wait on average no more than 4.5 months, in sharp
contrast to other centers in the region, whose wait times range
SINCE INCEPTION
from seven to 62 months.
In a kidney-pancreas transplant, the pancreas protects the new
kidney, allowing it to perform better and longer than a kidney
alone. Many dual transplant recipients are free of diabetes
255
years after their transplant. Additionally, Baylor had
a 100-percent rate of patient, kidney and pancreas survival
over the past two and a half years.
PANCREAS
TRANSPLANTS
SINCE INCEPTION
Pancreatic Cyst Evaluation
Pancreatic cysts can be benign, but 20 percent of
Kidney Transplant Volumes BUMC & BAS
pancreatic cancers start with a cyst. The Pancreatic Cyst
Program provides a fast, convenient way to have pancreatic
250
cysts evaluated and removed, if needed. A multidisciplinary
team of gastroenterologists, radiologists, pathologists and
surgeons evaluates each patient and determines the best
199
200
189
Dr. Bernard Fishbach
Medical Director of
194
191
189and Pancreas
Renal
Transplantation
150
course of action.
100
50
0
2010
2011
US Nat’l Avg: 94.7%
250
100
199
189
189
194
191
60
100
40
50
20
2010
2011
2012
2013
2014
Kidney Transplant Outcomes percent alive at one year
US Nat’l Avg: 94.7%
(SRTR Dec 2014)
94.7%
95.8%
2014
94.9%
(SRTR Dec 2014)
91.5%
94.7%
95.8%
94.9%
97.4%
2011
2012
2013
2014
80
150
0
2013
Kidney Transplant Outcomes percent alive at one year
Kidney Transplant Volumes BUMC & BAS
200
2012
0
2010
11
97.4%
ISLET
CELL
12
I S LE T CE L L
Patients with chronic pancreatitis face a life of
severe, debilitating pain and often long-term narcotic
dependence. At Baylor, there’s a clinical solution that
can restore their quality of life—a total pancreatectomy
and autologous islet cell transplant.
Auto Islet Cell Transplant
Allo-Islet Cell Transplantation
Baylor is the preeminent center in the Southwest and one
Pancreatic islet transplantation is still considered an
of the few in the world to offer this innovative therapy.
investigational procedure in the U.S. as a treatment
In the procedure, the pancreas and spleen are removed, and
for type 1 diabetes. But the past decade has seen
the patient’s islet cells are extracted. They are then infused
tremendous progress, and Baylor continues to contribute
into the patient’s liver, where they take hold and ideally
scientific knowledge. In allogenic islet transplantation,
produce insulin. Baylor researchers conducted a study to
surgeons transplant islets isolated from deceased donors
measure the improvement in patients’ post-transplant quality
into patients with type 1 diabetes. Baylor’s clinical
of life. The results, which showed dramatic improvement, were
experience has enabled bold research initiatives that
presented at the International Pancreas and Islet Cell Transplant
elevate the performance of islet cell transplantation not
Association in September, 2013. For patients, the results are
only in our center, but also throughout the field.
tangible: 70 percent are narcotic-free one year after surgery.
The Outcome: Preservation of Pancreatic Endocrine Function
Insulin Dependent
Achievement of Insulin Independence
32%
68%
HbA1c <5.7%
41%
59%
5.7– 6.4%
29%
12%
6.5 – 7.0%
>7%
17%
Despite removal of their pancreas,
40 percent of patients are free
of exogenous insulin and a large
majority of the patients have
favorable HbA1C profiles.
42%
71%
All Patients (n=81)
(Follow up: 16.7 +/− 1.7 mos)
Patients Followed Up Over 1 Yr (n=51)
(Follow up: 23.7 +/− 2.2 mos)
HbA1c Levels
HbA1c<7.0%
125
ISLET CELL
TRANSPLANTS
PERFORMED
SINCE INCEPTION
13
M EET
ASHLYN
ASHLYN BOLLINGER | Age 23 | Islet Cell Transplant
Ashlyn Bollinger learned she had chronic pancreatitis at age 17. Her condition became so bad that she had to drop out of
college after a year and a half, unable to eat or alleviate the constant, severe pain. “I did nothing but lie in bed— everything
hurt,” she says. In June 2014, Ashlyn had an auto islet cell transplant. Now she’s back to an active, busy life, free to pursue
any of her passions, from sports to dog rescue. She looks forward to going back to college and becoming a nurse. “That’s my
calling,” she says. “I want to find that patient who has chronic pancreatitis and say, ‘I know exactly what you’re going through.’”
14
I S LE T CE L L
Islet Cell Research
Narcotic Dependence
Recently, Baylor Research Institute was awarded a patent
Narcotic-dependent
Before TP-AIT
from the U.S. Patent Office for a potential strategy to
Narcotic-free
1 Year After TP-AIT
7%
improve the outcomes of islet cell transplantation for patients
with type 1 diabetes or chronic pancreatitis. Our researchers
29%
were first to report that transplanted islet cells are subject
to severe and inflammatory reaction, which damages them.
93%
71%
Experimental research at Baylor showed that Withaferin A
(WA), a plant-derived compound with anti-inflammatory and
anti-oxidant properties, can inhibit the inflammatory response
and protect islet cells from damage. Until now, no compound
with such benefits has been used in islet transplantation.
While 93 percent of our patients are narcotic-dependent before surgery, a
remarkable
are narcotic-free
one year after surgery. before surgery,
While
93%71percent
of our patients
are narcotic-dependent
a remarkable 71% are narcotic-free one year after surgery.
#2
IN THE NATION IN
AUTO ISLET
TRANSPLANT VOLUME
12 Major Centers Offering Islet Autotransplantation
Geneva, Switzerland
Leicester, UK
U.S. Centers:
Dallas, TX
Minneapolis, MN
Pittsburgh, PA
Cincinnati, OH
Charleston, SC
Chicago, IL
Birmingham, AL
Sendai, Japan
Seoul, S. Korea
Milan, Italy
15
Credit: SciePro / Science Source
HEART
16
HE A RT
When it comes to heart transplantation, Baylor’s role
is central—literally. Our location near the center of the
country puts us within just a few hours of donor hearts,
expanding the treatment options for patients nationwide.
Since the arrival of a new surgical team in 2012, the volume
a cardiothoracic surgical fellowship for transplant LVAD
of transplants has tripled in two years. And the median wait
training and are developing a fellowship for advanced heart
time for status 1A patients has shrunk to just seven days.
failure transplant training.
Our growth in volume and depth of experience have put
Baylor in an optimal philosophical position as well. We accept
high risk patients, even those that other centers have declined,
yet have maintained survival rates that exceed the national
average. We also have developed strong relationships with
other transplant centers and heart failure centers, welcoming
patients from across the nation, in some cases arranging
for patients to return to their original transplant center for
Our deep commitment to referring physicians continues to
expand and strengthen our referral network. We maintain
continuous contact with referring physicians, not only
updating them on their patients’ status at every turn but also
sharing as much of their patients’ care management as they
choose. These collaborations benefit patients as well, as they
can return home for follow-up care.
follow-up care. Patients and physicians may take advantage
Transplant
Volumes
Left Heart
Ventricular
Assist
Devices
of dual listing at two or more transplant centers, which can
Not
100 all patients are candidates for a heart transplant, but an
reduce the wait time for a transplant. Further, we collaborate
90
implantable
left ventricular assist device (LVAD) may be an
with transportation companies to provide a patient’s timely
80
option
for managing their advanced heart failure.
68In fact, the
102
70
arrival for their procedure.
60
Leading the transplant team are Gonzalo Gonzalez-Stawinski,
MD and Shelley Hall, MD. In addition to adding surgeons
and transplant cardiologists on the medical staff in late 2014,
we are expanding our midlevel clinical staff. We’ve instituted
102
50
40
30
30
24
HEART TRANSPLANTS
IN 2014
20
10
0
Heart Transplant Volumes
2010
2011
2012
2013
2014
Heart Transplant Outcomes percent alive at one year
102
100
US Nat’l Avg: 90.9%
100
(SRTR Dec 2014)
91.7%
96.7%
90
80
94.1%
86.1%
85.3%
2012
2013
80
68
70
60
60
43
50
40
30
43
40
30
24
20
20
10
0
2010
2011
2012
2013
Heart Transplant Outcomes percent alive at one year
US Nat’l Avg: 90.9%
2014
0
2010
2011
2014
17
M EET
TRENTON
TRENTON CARY | Age 24 | Heart Transplant
Trenton Cary is on his third heart. Born with a congenital heart defect, he had a heart transplant just shy of his first birthday.
That heart served him well for the next 20 years. At college he noticed a drop in his energy and chalked it up to lack of sleep.
But one day he was running to help a friend catch his loose dog and suffered a heart attack. Doctors discovered that his heart
was being rejected. Nine hours after Trenton was put on the transplant wait list, he received a new heart. Seven months later,
Trenton says, “I can do anything I want.” With the way he takes to volleyball, soccer, baseball and martial arts, it’s clear that
what he wants is to stay active.
18
HE A RT
shortage of donor organs makes it imperative that we offer
patients access to innovative heart-assist devices. We also
BAYLOR DALLAS IS ONE
practice shared care with referring physicians after patients
are released, including offering LVAD training for those who
OF ONLY TWO CENTERS
choose to be more involved in the ongoing management
of their patients’ care.
IN THE U.S. THAT PERFORM
The expansion of our transplant program and the addition
MORE THAN 75 HEART
of sophisticated circulatory support devices have moved
Baylor into a position to provide more advanced care for
TRANSPLANTS A YEAR
heart failure. For some patients who are too unstable for a
major intervention, Baylor offers extracorporeal membrane
oxygenation (ECMO). Unlike devices that support only
the left ventricle, ECMO can support both ventricles.
ECMO Transports By Year
Often needed on an emergency basis, ECMO may be used
to stabilize a patient so that physicians can determine if a
longer-term option is appropriate. We have transported
patients with ECMO from up to 390 miles away.
VAD Transplant Volumes
Heart transplantation remains the ultimate bi-ventricle
60
support. Now, due to Baylor’s efficient and thorough
evaluation of patients and short median wait times, many
patients can go straight to transplant without the interim
45
50
40
40
step of an LVAD implantation.
30
20
2012
2013 27 5
2014
Farthest
transport
28
with ECMO:
390 miles
1
16
23
Transport period: Nov 2012 – May 2014
10
0
VAD Transplant Volumes
2010
2011
2012
2013
2014
VAD Transplant Outcomes percent alive at one year
INTERMACS Post Implant Survival 2013 Q4: 78.00%
60
100
81.5%
45
50
82.6%
80
40
62.2%
40
65.0%
64.3%
2013
2014
60
30
28
27
23
40
20
20
10
0
2010
2011
2012
2013
VAD Transplant Outcomes percent alive at one year
2014
0
2010
2011
2012
19
Credit: SciePro / Science Source
LUNG
20
L UNG
For people living with lung diseases like cystic fibrosis,
pulmonary fibrosis, emphysema and other conditions,
every breath is a struggle. For such patients, Baylor’s
lung transplant team can offer a new lease on life.
The volume of transplants performed at Baylor puts
our program in the top 25 percent of centers nationally.
The Center for Advanced Heart and Lung Disease focuses
on more than lung transplants. We also offer a full range
Dr. David Mason
Joins Baylor Dallas’
Lung Transplant Team
of diagnostic tools and advanced therapies for patients with
complex, chronic and rare lung diseases. Patients receive
coordinated care from a multidisciplinary team of pulmonary
physician specialists, nurse practitioners, nurse coordinators,
respiratory therapists, dieticians and social workers.
Offering all diagnostic and therapeutic options in one center
is more convenient for patients. The team approach is even
more appreciated by referring physicians, who lack the time
to provide the complexity of diagnostic and therapeutic
options and education needed by these patients.
Patients with acute respiratory failure may be candidates for
circulatory support with extracorporeal membrane oxygenation
(ECMO), a therapy that Baylor also uses for patients with
heart failure. The implantable device is used primarily for
reversible lung conditions, such as pneumonia, or as a bridge
to lung transplant for patients on the waiting list.
David P. Mason, MD, is the chief of thoracic surgery and
lung transplantation for the Baylor Scott & White Health
system. Dr. Mason is an international leader in the field of lung
transplantation. Before joining Baylor Scott & White in 2014,
he was on the surgical staff at Johns Hopkins University and the
Cleveland Clinic in Cleveland, Ohio. He leads the department of
thoracic surgery at Baylor University Medical Center at Dallas and
the Center for Thoracic Surgery.
Dr. Mason has many research interests and is widely published in
all areas of thoracic surgery. He is the author of numerous articles
and book chapters. He is a member of multiple international
societies and leadership committees, including the Joint
Commission for Thoracic Surgery Education, the Thoracic Organ
Committee of the American Society of Transplant Surgeons, the
Interventional Chest/Diagnostic Procedures Network Steering
Committee of CHEST and the International Advisory Committee
of the American Association of Thoracic Surgery.
Patients with emphysema also have access to minimally
invasive lung volume reduction surgery (LVRS). Lung volume
reduction surgery is a procedure where surgeons remove
portions of diseased lung tissue damaged by severe emphysema.
By removing poorly functioning tissue, remaining lung tissue
can work more efficiently.
Baylor Dallas also offers patients access to clinical trials
evaluating potential therapeutic agents. Currently, we are
participating in clinical trials to evaluate two new drug
37
LUNG
TRANSPLANTS
IN 2014
21
M EET
CARRIE
CARRIE GIDDENS | Age 29 | Double Lung Transplant
As if growing up with cystic fibrosis wasn’t bad enough, Carrie Giddens lost her brother to the same disease. In the fall of
2012 she was a grieving sister, a new mother of twins and plagued with frequent lung infections. After spending most of
October in the hospital, she got home in time to take her boys trick-or-treating. Two days later she was in critical care and
crashing. The transplant team put Carrie on ECMO to keep her alive and fast-tracked her for a lung transplant. Before the
month was out she had new lungs and made it home in time for Christmas. “I was their first lung transplant patient to have
ECMO,” she says. “If I’d been at any other hospital, I don’t think I would have made it.”
22
15
11
10
L UNG
5
0
2010
2011
2012
2013
2014
Lung Transplant Outcomes percent alive at one year
Lung Transplant Volumes
40
37
100
93.8%
US Nat’l Avg: 87.7%
89.7%
91.9%
2013
2014
(SRTR Dec 2014)
35
29
29
79.3%
80
30
63.6%
25
60
20
15
16
40
11
10
20
5
0
100
2010
2011
2012
2013
2014
2012
93.8%
disease, also known as interstitial
pneumonia. Data presented
91.9%
Medical Center includes transplant pulmonologists, surgeons,
89.7%
US Nat’l Avg: 87.7%
at the American Thoracic
79.3% Society and published in the
coordinators, social workers, physical therapists, respiratory
New England Journal of Medicine showed positive benefits
therapists, anesthesiologists, nutritionists and nurses who
60
with both drugs.
40
With the recent additions to our medical and surgical team,
work together to provide the best possible quality outcomes
our program has extensive experience in the surgical and
medical care of lung transplant patients. This allows our
program to accept patients with complex conditions that
2010
2011
2012
2013
2014
other centers may refuse. In addition, we are actively involved
in research to improve outcomes after lung transplantation.
for patients. We provide a rapid, comprehensive evaluation to
determine the appropriateness and timing of transplantation.
Transplant outcomes at Baylor University Medical Center
are excellent and continue to improve with one-year survival
despite increased patient acuity. Waitlist times continue
to decrease as transplant volumes steadily increase. Baylor University Medical Center at Dallas is the top-ranked
hospital in North Texas and continues to be ranked as one
of America’s top hospitals by U.S. News & World Report.
M AY
0
2011
Our experienced lung transplant team at Baylor University
63.6%
20
2010
Lung Transplant Outcomes percent alive at one year
therapies, nintedanib and pirfenidone, for interstitial lung
(SRTR Dec 2014)
80
0
2012
Gene Peyton
DOUBLE LUNG TRANSPLANT
AT AGE 66
After receiving a double lung transplant, Reverend Gene Payton
says that overseeing his church’s food pantry — including delivering
food items and restocking shelves— is a labor of love. “I find it hard
to believe that I’m actually loving being able to work,” he says.
23
RESEARCH
24
R ESE A RCH
In 2014, physicians on the medical staff at the Baylor
Annette C. and Harold C. Simmons Transplant Institute
and Institute scientists gave 53 scientific presentations
around the world, and published 40 abstracts and
76 peer-reviewed publications.
Transplantation of the Liver, edited by Drs. Klintmalm at
Transplant Biorepository
Baylor Annette C. and Harold C. Simmons Transplant
We also created the Biorepository in 1985. Blood samples
Institute and Busuttil at UCLA, is the universally used
have been collected from organ donors and from transplant
textbook in liver transplantation. First published in 1996,
recipients at regular intervals for the rest of their lives. We took
the third edition was available in December 2014. Many of
the Biorepository public in November 2009 and immediately
the chapters in the textbook were authored by physicians on
received worldwide attention. Many presentations and
the medical staff at Baylor, as well as other world-recognized
scientific publications have resulted from our Biorepository.
leaders in their fields.
Moreover, Baylor is a global leader in the field of antibody-
Another textbook, Medical Care of the Liver Transplant Patient,
was published in December 2012 and authored/edited by
caused injury to liver transplants. We are now establishing
biorepositories for the other organ transplants.
James Trotter, MD, medical director of liver transplantation at
It takes more than research databases and biorepositories to
Baylor Dallas, and Pierre-Alain Clavien, MD, PhD, professor
generate research. The investigators are critical. These are the
and chairman, Department of Transplantation Surgery at
individuals who are driven to find the answers to unanswered
the University of Zurich, Switzerland. This textbook for
questions from medical school, residency and fellowship.
hepatologists is the most current clinical guide on how
They come to us with a research history, but first they have
to best treat liver transplant recipients.
to be identified, recruited and then mentored. Our worldwide
Liver Transplant Research Database System
In 1985, at the beginning of the liver transplant program,
Baylor created the Liver Transplant Research Database System
(LTRDS). Today it’s the longest existing, most detailed liver
transplant research database in the world. Collecting data
from patients before transplant and throughout their lives, this
research database has been the foundation for our worldwide
recognition as a major contributor in liver transplantation.
presence in the transplant community is the direct outcome
of Baylor’s dedication to nurturing the passions of researchers
and pioneering transplant medicine— a dedication we have
embraced since our beginning in 1985. Both Simmons
Transplant Institute and the Baylor Health Care System
Foundation are committed to continue raising community
support for this goal. The future of transplantation and the
lives of our patients depend on it.
Due to significant donations made to Simmons Transplant
Institute, we are developing such research databases for our
heart, lung, kidney, pancreas and islet transplant divisions.
We plan to go live with these updated research databases
in 2015. With complete new heart and lung transplant
53
SCIENTIFIC
PRESENTATIONS
WORLDWIDE
teams, we expect major research activity to develop in
these organ systems similar to that for liver transplant.
25
OUTREACH
AUSTIN·AMARILLO· MCKINNEY· FRISCO
WA X A H A C H I E · O D E S S A · L U B B O C K
LONGVIEW·MIDLOTHIAN & BEYOND
26
O UTRE A CH
For people who live with liver, kidney or heart disease,
but do not live near Baylor Annette C. and Harold C.
Simmons Transplant Institute, we bring 30 years of
transplant experience to them.
Teams of physicians, nurses and assistants travel to outreach
LVADs, both as a bridge to transplant and as a destination
clinics throughout Texas, delivering world-renowned
therapy. With more understanding of the LVADs, physicians
transplantation medicine to an expanding network of
are better equipped to refer their patients to the program and,
communities. The clinics are an outreach service of Health
if they choose, to assist with managing their patients when they
Texas Provider Network.
return home after implantation.
Liver Health Clinics
Kidney Transplant Outreach Clinic
Baylor’s Liver Health Clinics bring liver care to those
Many people do not believe they are eligible for kidney
unable to travel to Baylor Dallas or Baylor Fort Worth to
transplant when, in fact, they are. For others, routinely
see a liver specialist. Hepatologists travel to nine outreach
traveling to the Dallas Fort Worth area isn’t feasible.
clinics throughout Texas to see patients with viral hepatitis,
To serve such patients in West Texas and the Panhandle,
cirrhosis, liver masses and other liver conditions, providing
Baylor established weekly Kidney Transplant Outreach
people in outlying communities access to a wider range
Clinics in Lubbock and Amarillo to offer evaluations and
of treatment options.
post-transplant care. When a patient receives a kidney
Outreach Centers for Advanced Heart Disease
Baylor’s innovative outreach program gives patients in areas
with limited health resources access to a full range of treatment
options for advanced heart disease. Outreach teams travel to six
locations in Texas to evaluate heart disease patients, including
evaluation for heart transplantation or LVADs. Often, LVAD
implantation is not available in smaller, outlying communities.
Baylor also has initiated LVAD Visitation Days, which allow
transplant, our goal is to get the patient home within two
to three weeks, where the patient can be closely followed by
the transplant team in the outreach clinic. Baylor maintains
close communication with the patient’s referring nephrologist,
keeping them continually apprised of their patient’s progress.
2014 Transplant Outreach Clinics
Liver
Kidney
Heart
Amarillo
referring cardiologists to come to Baylor Dallas to learn about
Frisco
IN 2014
Lubbock
9
5
2
Abilene
LIVER CLINICS
McKinney
Dallas-Fort Worth
Grand Prairie
Midlothian
Waxahachie
Longview
Odessa
TEXAS
Austin
HEART CLINICS
KIDNEY CLINICS
27
DONOR
COMMUNITY
28
C O MMUNI TY
It takes a village to raise donor awareness. It takes living
donors and recipients to promote more participation.
It takes public and private entities collaborating to boost
enrollment on registries. And it takes an institution committed
to spotlighting the immeasurable value of the gift of life.
Baylor Honors DPS for Dramatic Rise in Organ Donors
Living Donor Wall
It is rare that a government agency receives an award from the
In June 2013, Baylor University Medical Center became the
private sector for doing a good job. But Baylor Health Care
home of the Living Donor Wall, honoring living donors who
System turned the tables, awarding the Texas Department of
have made kidney or liver donations going back to 2011.
Public Safety (DPS) the Barry and Ceil Newman Award for
Consenting donors’ names are added to the wall yearly, in
its efforts to lift the state’s organ donation registry from the
recognition of their generosity and compassion and to raise
bottom of the heap to the nation’s fastest-growing list. The
awareness of organ donation.
award was presented May 12, 2014. Donor Advocate Symposium
Only about 2 percent of Texas adults were registered organ
The third annual Donor Advocate Symposium, led by Giuliano
donors in 2009, according to the nonprofit Donate Life Texas.
Testa, MD, was held in October 2014. Because living donor
That rate has risen to about 25 percent, according to DPS. transplantation is so vital to patients with severe kidney or liver
The reason? The creation of an organ donor registry by
two state agencies—the DPS and the Department of
Motor Vehicles— and three organ tissue recovery agencies.
The registry makes it easy for residents to sign up at their local
DPS office when applying for or renewing a driver’s license
or identification card.
Göran Klintmalm, MD, PhD, FACS, presents the Barry and Ceil Newman Award to
Salestus Winkley from the Department of Public Safety May 12, 2014. Dr. Klintmalm is
chairman and chief of Baylor’s Annette C. and Harold C. Simmons Transplant Institute.
disease or end-stage organ failure, the symposium helps nurses,
clinicians, social workers and clergy communicate the living
donor option to patients, family, friends and potential living
donors. Topics covered include cost, psychosocial and ethical
issues, long-term donor health, paired donation, transplant
outcomes and the role of the media. The symposium’s goal
is to increase participation in the living donor process.
Christina Pippin, John Brinlee, Jr., Giuliano Testa, MD, FACS, and Michelle Brennan Hall at
the second annual Donor Advocate Symposium.
29
P UB LICATI O N S
2013 Liver and Kidney Publications
Klintmalm G, O’Farrely C. Taking the rap:
Multiple effects of blocking mammalian target
of rapamycin. Journal of Hepatology 2013,
Jan;57(1): 1-3.
McKenna GJ, Trotter JF, Klintmalm E, Ruiz
R, Onaca N, Testa G, Saracino G, Levy MF,
Goldstein RM, Klintmalm GB. Sirolimus and
cardiovascular disease risk in liver transplantation.
Transplantation; Vol.95: No 1: Jan. 15, 2013:
215-221.
Kim, PTW, Onaca N., Chinnakotla S., Davis GL,
Jennings LW, McKenna GJ, Ruiz RM, Levy MF,
Goldstein R, Klintmalm GB. Tumor biology and
pre-transplant loco regional treatments determine
outcomes in patients with T3 hepatocellular
carcinoma undergoing liver transplantation. Clin
Transp. Mar-Apr 2013;Vol.27;No.2;Pg:311-318.
O’Leary JG, McKenna GJ, Klintmalm GB, Davis
GL. Effect of Telaprevir on the Pharmacokinetics
of Sirolimus in Liver Transplant Recipients. Liver
Transplantation 19:463-465, 2013; Letter to the
Editor.
O’Leary JG, Gebel HM, Ruiz R, Bray RA, Marr
JD, Zhou XJ, Shiller SM, Susskind BM, Kirk
AD, and Klintmalm GB. Class II alloantibody
and mortality in simultaneous liver-kidney
transplantation. AJT 2013; Apr; 13 (4): 954-60.
Biggins SW, Trotter J, Gralla J, Burton JR,
Bambha KM, Dodge J, Brocato M, Cheng L,
McQueen M, Forman L, Chang M, Kam I,
Everson G, Spritz RA, Klintmalm G, Rosen HR.
Differential effects of donor and recipient IL28B
and DDX58 SNP’s on severity of HCV after liver
transplantation. Jour Hep. 2013; May:58(5):
969-76.
O’Leary JG, Klintmalm GB. Impact of
donor-specific antibodies on results of liver
transplantation. Liver Transplantation 2013;
Jun;Vol. 8; No. 3, Pg. 279-284.
Kaneku H, O’Leary JG, Banuelos N, Jennings
LW, Susskind BM, Klintmalm GB, and Terasaki
PI. De novo donor-specific HLA antibodies
decrease patient and graft survival in liver
transplant recipients. AJT, June 2013: Vol 13:
Issue 6: 1541-1548.
Campsen J, Zimmerman M, Trotter J, Hong J,
Freise C, Brown R, Cameron A, Ghobrial M,
Kam I, Busuttil R, Saab S, Holt C, Emond J,
Stiles J, Lukose T, Chang M, and Klintmalm G.
Liver transplantation for hepatitis B liver disease
and concomitant hepatocellular carcinoma in the
United States with hepatitis B immunoglobulin
and nucleoside/nucleotide analogues. Liver Transp
2013; Vol. 19; Pg. 1020-1029.
O’Leary JG, Kaneku H, Jennings LW, Banuelos
N, Susskind BM, Terasaki PI, and Klintmalm GB.
Preformed class II donor-specific antibodies are
associated with an increased risk of early rejection
after liver transplantation. Liver Transplantation
Vol. 19; No. 9; Sept. 2013 pg. 973-980.
O’Leary JG, McKenna G, Klintmalm GB,
Davis GD. The effect of Telaprevir on the
pharmacokinetics of Sirolimus in liver transplant
recipients. Liver Transplantation 19:463-5, 2013.
30
Campsen J, Zimmerman M, Trotter J, Hong J,
Freise C, Brown RS Jr., Cameron A, Ghobrial
M, Kam I, Busuttil R, Saab, Holt C. Emond JC,
Stiles JB, Lukose T, Chang MS, and Klintmalm
G. Multicenter review of liver transplant for
hepatitis B-related liver disease: disparities in
gender and ethnicity. Clinical Transplantation,
Vol. 27; No. 6; Nov-Dec. 2013; pg. 829-837.
O’Leary JG, Kaneku H, Demetris AJ, Marr JD,
Shiller SM, Susskind BM, Tillery W, Terasaki PI,
Klintmalm GB. Antibody mediated rejection as a
contributor to previously unexplained early liver
allograft loss. Liver Transplantation 2013; Nov 6;
doi: 10.1002/lt.23788.
Auxiliary liver transplant is an ineffective
treatment of primary hyperoxaluria. Trotter
JF, Milliner D. Am J Transplant. 2014 Jan;
14(1):241. doi: 10.1111/ajt.12535. Epub 2013
Dec 12.
Risk of Hernia Incarceration following
Transjugular Intrahepatic Portosystemic Shunt
Placement. Smith MT, Rase B, Woods A, Trotter
J, Gipson M, Kondo K, Ray C, Durham J. J
Vasc Interv Radiol. 2014 Jan;25(1):58-62. doi:
10.1016 /j.jvir .2013. 09.003. Epub 2013 Oct 24.
Sporothrix schenckii Lymphadentitis in a Male
with X-linked Chronic Granulomatous Disease.
A Comparison of Outcomes Between OKT3
and Antithymocyte Globulin for Treatment of
Steroid-Resistant Rejection in Hepatitis C Liver
Transplant Recipients. Benjamin MM, Dasher KJ,
Trotter JF. Transplantation. 2013 Oct 17.
Is disease recurrence still relevant to graft survival?
Trotter JF. Liver Transpl. 2013 Nov;19 Suppl
2:S49-55. doi: 10.1002/lt.23750.
Multicenter review of liver transplant for hepatitis
B-related liver disease: disparities in gender and
ethnicity. Campsen J, Zimmerman M, Trotter
J, Hong J, Freise C, Brown RS Jr, Cameron A,
Ghobrial M, Kam I, Busuttil R, Saab S, Holt
C, Emond JC, Stiles JB, Lukose T, Chang MS,
Klintmalm G. Clin Transplant. 2013 Nov; 27
(6):829-37. doi: 10.1111/ctr.12224. Epub 2013
Sep 3.
Computerized assessment of competence-related
abilities in living liver donors: the Adult-to-Adult
Living Donor Liver Transplantation Cohort
Study. Freeman J, Emond J, Gillespie BW,
Appelbaum PS, Weinrieb R, Hill-Callahan P,
Gordon EJ, Terrault N, Trotter J, Ashworth A,
Dew MA, Pruett T; A2ALL Study Group. Clin
Transplant. 2013 Jul-Aug;27(4):633-45. doi:
10.1111/ctr.12184. 2013 Jul 16.
Liver transplantation for hepatitis B liver disease
and concomitant hepatocellular carcinoma in the
United States with hepatitis B immunoglobulin
and nucleoside/nucleotide analogues. Campsen
J, Zimmerman M, Trotter J, Hong J, Freise C,
Brown R, Cameron A, Ghobrial M, Kam I,
Busuttil R, Saab S, Holt C, Emond J, Stiles J,
Lukose T, Chang M, Klintmalm G. Liver Transpl.
2013 Sep;19(9):1020-9. doi: 10.1002/lt.23703.
Calcineurin inhibitor-free mycophenolate mofetil/
sirolimus maintenance in liver transplantation: the
randomized spare-the-nephron trial. Teperman
L, Moonka D, Sebastian A, Sher L, Marotta P,
Marsh C, Koneru B, Goss J, Preston D, Roberts
JP; Spare-the-Nephron Trial Liver Transplantation
Study Group. Liver Transpl. 2013 Jul;19(7):67589. doi: 10.1002/lt.23658.
Underreporting of liver transplant waitlist
removals due to death or clinical deterioration:
results at four major centers. Goldberg D,
French B, Trotter J, Shetty K, Schiano T,
Reddy KR, Halpern SD. Transplantation.
2013 Jul 27;96(2):211-6. doi: 10.1097/
TP.0b013e3182970619.
Early use of renal-sparing agents in liver
transplantation: a closer look. Trotter JF,
Grafals M, Alsina AE. Liver Transpl. 2013
Aug;19(8):826-42. doi: 10.1002/lt.23672.
Predicting end-stage renal disease after liver
transplant. Israni AK, Xiong H, Liu J, Salkowski
N, Trotter JF, Snyder JJ, Kasiske BL. Am J
Transplant. 2013 Jul;13(7):1782-92. doi:
10.1111/ajt.12257. 2013 May 13.
Ascites with elevated protein content as the
presenting sign of constrictive pericardial disease.
George BA, Deprisco G, Trotter JF, Henry AC
3rd, Stoler RC. Proc (Bayl Univ Med Cent). 2013
Apr;26(2):168-70.
Kayser-Fleischer rings of acute Wilson’s disease.
Mantas AM, Wells J, Trotter J. Proc (Bayl Univ
Med Cent). 2013 Apr; 26(2):166-7.
Differential effects of donor and recipient IL28B
and DDX58 SNPs on severity of HCV after liver
transplantation. Biggins SW, Trotter J, Gralla J,
Burton JR Jr, Bambha KM, Dodge J, Brocato
M, Cheng L, McQueen M, Forman L, Chang
M, Kam I, Everson G, Spritz RA, Klintmalm G,
Rosen HR. J Hepatol. 2013 May;58(5):969-76.
doi: 10.1016/j.jhep.2012.12.027. 2013 Jan 15.
Nonalcoholic fatty liver disease and the metabolic
syndrome: clinical implications and treatment.
Rahimi RS, Landaverde C. Nutr Clin Pract. 2013
Feb;28(1):40-51. 2013 Jan 3. Review.
Wong F, O’Leary JG, Reddy KR, Patton
H, Kamath PS, Fallon MB, Garcia-Tsao G,
Subramanian RM, Malik R, Maliakkal B, Thacker
LR, Bajaj JS. Validation of the New Consensus
Definition of Acute Kidney Injury in Predicting
Mortality in Infected Cirrhotic Patients.
Gastroenterology 145: 1280, 2013.
Michael M, Campbell P, Gebel H, Randhawa P,
Rodriguez R, Colvin R, Conway J, Hachem R,
Halloran P, Keshavjee S, Nickerson P, Murphey C,
O’Leary J, Reeve J, Tinckam K, Reed EF. Meeting
Report: 2012 CST- AST JOINT SESSION:
Precision Diagnostics in Transplantation: From
Bench to Bedside. AJT 13:562-8; 2013.
PTW Kim, J-H Jang, EG Atenafu, S Fischer, PD
Greig, ID McGilvray, AC Wei, C-A Moulton,
S Gallinger, SP Cleary. Outcomes after liver
resection and subsequent multimodality treatment
of recurrence for multifocal hepatocellular
carcinoma: An experience at North American
Center. Br J Surg 2013;100:1516-1422.
PTW Kim, N Onaca, S Chinnakotla, GL
Davis, LW Jennings, GJ McKenna, RM Ruiz,
MF Levy, R Goldstein, and GB Klintmalm.
Tumor biology and pretransplant locoregional
treatments determine outcomes in patients with
T3 hepatocellular carcinoma undergoing liver
transplantation. Clin Transplant 2013;27(2):311-8.
PTW Kim, AC Wei, EG Atenafu, D
Cavallucci, SP Cleary, CA Moulton, PD Greig,
S Gallinger, S Serra, ID McGilvray. Partial
versus circumferential portal vein resections
in pancreaticoduodenectomy for pancreas
cancer: Planning makes a difference. Br J Surg
2013;100(10):1349-56.
P U B L I C ATI O NS
Wong F, O’Leary JG, Reddy KR, Patton
H, Kamath PS, Fallon MB, Garcia-Tsao G,
Subramanian RM, Malik R, Maliakkal B, Thacker
LR, Bajaj JS. Validation of the New Consensus
Definition of Acute Kidney Injury in Predicting
Mortality in Infected Cirrhotic Patients.
Gastroenterology 145: 1280, 2013.
Michael M, Campbell P, Gebel H, Randhawa P,
Rodriguez R, Colvin R, Conway J, Hachem R,
Halloran P, Keshavjee S, Nickerson P, Murphey C,
O’Leary J, Reeve J, Tinckam K, Reed EF. Meeting
Report: 2012 CST-AST JOINT SESSION:
Precision Diagnostics in Transplantation: From
Bench to Bedside. AJT 13:562-8; 2013.
Rahimi RS, Guntipalli P, Rockey DC.
Worldwide Practices for Pharmacologic Therapy
in Esophageal Variceal Hemorrhage. Scand J
Gastroenterol. 2013 Nov 30.
Singal AG, Rahimi RS, Clark C, Ma Y, Cuthbert
JA, Rockey DC, Amarasingham R.An Automated
Model Using Electronic Medical Record Data
Identifies Patients with Cirrhosis at High Risk for
Readmission. Clin Gastroenterol Hepatol. 2013
Oct; 11(10):1335-1341.
Rahimi RS, Elliott AC, Rockey DC. Altered Mental
Status in Cirrhosis: Etiologies and Outcomes. J
Investig Med. 2013 Apr; 61(4):695-700.
Rahimi RS, Landaverde C. Nonalcoholic Fatty
Liver Disease and the Metabolic Syndrome:
Clinical Implications and Treatment. Nutr Clin
Pract. 2013 Feb: 28 (1):40-51.
A Comparison of Outcomes Between OKT3
and Antithymocyte Globulin for Treatment of
Steroid-Resistant Rejection in Hepatitis C Liver
Transplant Recipients. Benjamin MM, Dasher KJ,
Trotter JF. Transplantation. 2013 Oct 17.
Early use of renal-sparing agents in liver
transplantation: a closer look. Trotter JF,
Grafals M, Alsina AE. Liver Transpl. 2013
Aug;19(8):826-42. doi: 0.1002/lt.23672.
Predicting end-stage renal disease after liver
transplant. Israni AK, Xiong H, Liu J, Salkowski
N, Trotter JF, Snyder JJ, Kasiske BL. Am J
Transplant. 2013 Jul;13(7):1782-92. doi:
10.1111/ajt.12257. 2013 May 13.
Ascites with elevated protein content as the
presenting sign of constrictive pericardial disease.
George BA, Deprisco G, Trotter JF, Henry AC
3rd, Stoler RC. Proc (Bayl Univ Med Cent). 2013
Apr;26(2):168-70.
Computerized assessment of competence-related
abilities in living liver donors: the Adult-to-Adult
Living Donor Liver Transplantation Cohort
Study. Freeman J, Emond J, Gillespie BW,
Appelbaum PS, Weinrieb R, Hill-Callahan P,
Gordon EJ, Terrault N, Trotter J, Ashworth A,
Dew MA, Pruett T; A2ALL Study Group. Clin
Transplant. 2013 Jul-Aug;27(4):633-45. doi:
10.1111/ctr.12184. 2013 Jul 16.
Underreporting of liver transplant waitlist
removals due to death or clinical deterioration:
results at four major centers. Goldberg D,
French B, Trotter J, Shetty K, Schiano T,
Reddy KR, Halpern SD. Transplantation.
2013 Jul 27;96(2):211-6. doi: 10.1097/
TP.0b013e3182970619.
Saracino G, Jennings LW, Hasse JM. Basic
statistical concepts in nutrition research. Nutr
Clin Pract. 2013 Apr:28(2):182-93.
31
Lagow EE, Leeper BB, Jennings LW, Ramsay MA.
Incidence and severity of respiratory insufficiency
detected by transcutaneous carbon dioxide
monitoring after cardiac surgery and intensive care
unit discharge. Proc (Baylor University).
West Nile Virus Infection in Kidney and
Pancreas Transplant Recipients in the DallasFort Worth Metroplex During the 2012 Texas
Epidemic. Yango AF, Fischbach BV, Levy M,
Chandrakantan A, Tan V, Spak C, Melton L, Rice
K, Barri Y, Rajagopal A, Klintmalm G. Saracino
G, Jennings LW, Hasse JM. Basic statistical
concepts in nutrition research. Nutr Clin Pract.
2013;28(2):182-193.
Hasse JM. Developing the “write” skills for
publishing. Nutr Clin Pract. 2013;28(2):153-157.
Hasse JM. Nutrition and liver disease: complex
connections. Nutr Clin Pract.2013;28(1):12-14.
(editorial)
2014 Liver and Kidney Publications
Klintmalm GB, Feng S, Lake JR, Vargas HE,
Wekerle T, Agnes S, Brown KA, Nashan B,
Rostaing L, Meadows-Shropshire S, Agarwal M,
Harler MB, Garcia-Valdecasas JC. Belataceptbased immunosuppression in de novo liver
transplant recipients: 1-year experience from
a phase II randomized study. AJT; 2014 Aug;
14(8):1817-27.
Rahimi RS, Singal AG, Cuthbert JA, Rockey DC.
Lactulose vs. Polyethylene Glycol 3350-Electrolyte
Solution for Treatment of Overt Hepatic
Encephalopathy: The HELP Randomized Clinical
Trial. JAMA Internal Medicine; 2014 Nov 1;
174(11):1727-33.
Rahimi RS, Rockey DC. Hepatic encephalopathy:
how to test and treat. Curr Opinion
Gastroenterology; 2014 May; 30(3):265-71.
Rahimi RS, Guntipalli P, Rockey DC. Worldwide
practices for pharmacologic therapy in esophageal
variceal hemorrhage. Scand J Gastroenterology;
2014 Feb; 49(2):131-7.
Perrillo RP, Di Bisceglie AM, Lok AS, Martin P,
Terrault N, Hoofnagle JH. Recent FDA warnings
on hepatitis B reactivation with immunesuppressing and anti-cancer drugs: Just the tip of
the iceberg? Hepatology; 2014 Nov 21.
Perrillo RP, Hwang JP, Barbo AG. Hepatitis B
reactivation during cancer chemotherapy: an
international survey of the membership of the
American Association for the Study of Liver
Diseases. Journal of Viral Hepatology; 2014 Sep
15.
Perrillo RP, Gish R, Falck-Ytter YT. American
Gastroenterological Association Institute Technical
Review on Prevention and Treatment of Hepatitis
B Reactivation during Immunosuppressive Drug
Therapy. Gastroenterology; 2014 Oct 31.
Klintmalm GB, Saab S, Hong JC, Nashan B. The
role of mammalian target of rapamycin inhibitors
in the management of post-transplant malignancy.
Clinical Transplantation; 2014 Jun; 28(6):635-48.
Asrani SK, Shah VH. Alcohol Related Liver
Damage. Expert Round Table; July 2014: 65:7
Gastroenterology and Endoscopy News.
Klintmalm GB. Carl Gustav Groth MD, PhD.
Clinical Transplantation 2014 Apr; 28(4):383.
Asrani SK, Kamath PS. Editorial: neutrophil
dysfunction in patients with cirrhosis. Aliment
Pharmacol Ther; 2014 Oct;40(8):986.
Klintmalm GB, Nashan B. The Role of mTOR
Inhibitors in Liver Transplantation: Reviewing
the Evidence. Journal of Transplantation;
2014:845438.
Asrani SK. Liver transplantation for NASH. Clin
Gastroenterol Hepatol.; 2014 Mar;12(3):403-4.
Trotter JF, Lizardo-Sanchez L. Everolimus in
liver transplantation. Current Opinion Organ
Transplant; 2014 Dec; 19(6):578-82.
Trotter JF. Challenges in living donor liver
transplantation. Clinical Liver Dis.; 2014 Aug;
18(3):651-60; 2014.05.007.
Trotter JF, Goldberg DS, Krok K, Batra S, Kawut
SM, Fallon MB. Impact of the hepatopulmonary
syndrome MELD exception policy on outcomes
of patients after liver transplantation: an analysis
of the UNOS database. Gastroenterology; 2014
May; 146 (5):1256-65.e1.
Trotter JF, Valley MA, Thomas D, Ginde AA,
Lowenstein SR, Honigman B. The relationship
between hepatopulmonary syndrome and
altitude. Canadian Journal of Gastroenterology &
Hepatology; 2014 Mar; 28(3):140-2.
Trotter JF, Benjamin MM, Dasher KJ. A
comparison of outcomes between OKT3 and
antithymocyte globulin for treatment of steroidresistant rejection in hepatitis C liver transplant
recipients. Transplantation; 2014 Feb 27;
97(4):470-3.
Trotter JF, Milliner D. Auxiliary liver transplant is
an ineffective treatment of primary hyperoxaluria.
American Journal of Transplantation; 2014 Jan;
14(1):241.
Asrani SK, Talwalkar JA, Kamath PS, Shah
VH, Saracino G, Jennings L, Gross JB. Role of
magnetic resonance elastography in compensated
and decompensated disease. J Hepatol.; 2014
May;60(5):934-9.
Asrani SK, Wiesner RH, Trotter JF, Klintmalm G,
Katz E, Maller E, Roberts J. De novo sirolimus
and reduced-dose tacrolimus versus standard-dose
tacrolimus after liver transplantation: The 20002003 phase II prospective randomized trial. AJT;
Feb; 14(2):356-66.
Asrani SK, O’Leary LG. Acute-on-chronic liver
failure. Clinical Liver Disease Aug; 18(3):561-74.
Asrani SK, Davis GL. Impact of birth cohort
screening for hepatitis C. Curr Gastroenterol;
2014 Apr;16 (4):381.
Asrani SK, Kumar S, Kamath PS. Epidemiology,
Diagnosis and Early Patient Management of
Esophagogastric Hemorrhage. Gastroenterol
Clinical North Am.; 2014 Dec; 43(4):765-782.
O’Leary JG. Debate—a bridge too far:
Nonalcoholic fatty liver disease will not exhaust
the donor pool. Liver Transpl.; 2014 Nov;20
Suppl 2:s38-41.
O’Leary JG, Schiller SM, Bellamy C, Nalesnik
MA, Kaneku H, Jennings LW, Isse K, Terasaki PI,
Klintmalm GB, Demetris AJ. Acute liver allograft
antibody-mediated rejection: an inter-institutional
study of significant histopathological features.
Liver Transpl.; 2014 Oct;20(10):1244-55.
31
P UB LICATI O N S
O’Leary JG, Campos-Varela I, Lai JC, Verna
EC, Todd Stravitz R, Forman LM, Trotter JF,
Brown RS, Terrault NA. Hepatitis C Genotype
Influences Post-Liver Transplant Outcomes.
Transplantation; 2014 Sep 10.
Burton JR, O’Leary JG, Verna EC, Saxena V,
Dodge JL, Stravitz RT, Levitsky J, Trotter JF,
Everson GT, Brown RS Jr, Terrault NA. A US
multicenter study of hepatitis C treatment of liver
transplant recipients with protease-inhibitor triple
therapy. J Hepatol.; 2014 Sep;61(3):508-14.
O’Leary JG, Reddy KR, Wong F, Kamath PS,
Patton HM, Biggins SW, Fallon MB, GarciaTsao G, Subramanian RM, Malik R, Thacker
LR, Bajaj JS. Long-term Use of Antibiotics and
Proton Pump Inhibitors Predict Development
of Infections in Patients with Cirrhosis. Clin
Gastroenterol Hepatol.; 2014 Aug 12. pii: S15423565(14)01146-X.
Bajaj JS, O’Leary JG, Reddy KR, Wong F,
Biggins SW, Patton H, Fallon MB, Garcia-Tsao
G, Maliakkal B, Malik R, Subramanian RM,
Thacker LR, Kamath PS. Survival in infectionrelated acute-on-chronic liver failure is defined
by extrahepatic organ failures. Hepatology; 2014
Jul;60(1):250-6.
O’Leary JG, Kaneku H, Jennings L, Susskind
BM, Terasaki PI, Klintmalm GB. Donorspecific alloantibodies are associated with fibrosis
progression after liver transplantation in hepatitis
C virus-infected patients. Liver Transpl.; 2014
Jun;20(6):655-63.
O’Leary JG, Demetris AJ, Friedman LS,
Gebel HM, Halloran PF, Kirk AD, Knechtle
SJ, McDiarmid SV, Shaked A, Terasaki PI,
Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle
ES, Zachary AA, Klintmalm GB. The role
of donor-specific HLA alloantibodies in liver
transplantation. AJT; 2014 Apr;14(4):779-87.
O’Leary JG, Kaneku H, Demetris AJ, Marr JD,
Shiller SM, Susskind BM, Tillery GW, Terasaki
PI, Klintmalm GB. Antibody-mediated rejection
as a contributor to previously unexplained
early liver allograft loss. Liver Transpl.; 2014
Feb;20(2):218-27.
O’Leary JG, Wong F, Reddy KR, Kamath PS,
Garcia-Tsao G, Maliakkal B, Subramanian
RM, Thacker LR, Bajaj JS; On behalf of North
American Consortium in the Study of EndStage Liver Disease. A cut-off serum creatinine
value of 1.5mg/dL for AKI — To be or not
to be. J Hepatol.; 2014 Dec 5. pii: S01688278(14)00888-5.
Serrano PE, Cleary SP, Dhani N, Kim PT, Greig
PD, Leung K, Moulton CA, Gallinger S, Wei AC.
Improved Long-Term Outcomes After Resection
of Pancreatic Adenocarcinoma: A Comparison
Between Two Time Periods. Ann Surg Oncol.;
2014 Oct 28.
32
Kim PT, Saracino G, Jennings L, Ramsay M,
McKenna GJ, Testa G, Anthony TL, Onaca N,
Ruiz RM, Goldstein RM, Levy MF, Klintmalm
GB. Ratio of hepatic arterial flow to recipient
body weight predicts biliary complications after
deceased donor liver transplantation. HPB
(Oxford); 2014 Jul 18.
Zarghouni M, Cura M, Kim PT, Testa G,
Klintmalm GB. Segmental biliary duct N-butyl
cyanoacrylate ablation in a transplant liver for
a biliary leak after hepaticojejunostomy. Liver
Transpl.; 2014 Jun;20(6):739-41.
Kim PT, Temple S, Atenafu EG, Cleary SP,
Moulton CA, McGilvray ID, Gallinger S, Greig
PD, Wei AC. Aberrant right hepatic artery in
pancreaticoduodenectomy for adenocarcinoma:
impact on resectability and postoperative outcomes.
HPB (Oxford); 2014 Mar;16(3):204-11.
2014 Islet Cell Publications
“Alleviation of instant blood-mediated
inflammatory reaction in autologous conditions
through treatment of human islets with NF-κB
inhibitors.” T. Itoh, M.A. Kanak, F. Kunnathodi,
M.C. Lawrence, M.F. Levy, S. Murali, B.
Naziruddin, R. Shahbazov, J.A. SoRelle, M.
Takita. Transplantation. 98(5): 578-584. 2014.
“A new method for generating insulin-secreting
cells from human pancreatic epithelial cells
after islet isolation transformed by Neuro
D1.” S. Chen, D. Chujo, P. Grayburn, T.
Itoh, S. Iwahashi, M.F. Levy, S. Matsumoto,
B. Naziruddin, H. Noguchi, M. Shimoda, K.
Sugimoto, M. Takita. Human Gene Therapy
Methods. 25(3): 206-219. 2014.
Testa G. Ethical issues regarding related and
nonrelated living organ donors. World J Surg.;
2014 Jul;38(7):1658-63.
“Elevation of high-mobility group box 1 after
clinical autologous islet transplantation and its
inverse correlation with outcomes.” P.T. Coates,
D. Chujo, W. Chung, A. Dennison, T. Itoh, S.
Iwahashi, M.A. Kanak, M.F. Levy, S. Matsumoto,
B. Naziruddin, N. Onaca, A.M. Rahman, M.
Shimoda, M. Takita, Y. Tamura. Cell Transplant.
23(2): 153-165. 2014.
Laux AT, Testa G, Goldstein RM, Cavaness KM.
The management of a complex bile duct injury
after laparoscopic cholecystectomy. Am Surg.;
2014 Jun;80(6):E175-8. “Evidence for instant blood-mediated
inflammatory reaction in clinical autologous
islet transplantation.” T. Itoh, S. Iwahashi, M.A.
Kanak, M.F. Levy, B. Naziruddin, M.
Kheradmand T, Anthony TL, Harland RC, Testa
G, Hart J, Renz J, Te HS, Marino SR. Antibodymediated rejection in ABO compatible husband
to wife living donor liver transplant and
review of the literature. Hum Immunol.; 2014
Jun;75(6):578-83.
Takita. American Journal of Transplantation.
14(2): 428- 437. 2014.
Testa G, deSante J, Caplan A, Hippen B, Lantos
JD. Was Sarah Murnaghan treated justly?
Pediatrics; 2014 Jul;134(1):155-62.
Hafzalah M, Azzam R, Testa G, Hoehn KS.
Improving the potential for organ donation in
an inner city Muslim American community: the
impact of a religious educational intervention.
Clin Transplant.; 2014 Feb;28(2):192-7.
2013 Islet Cell Publications
“Autoimmune chronic pancreatitis with IgG4related pancreatic pseudocyst in a patient
undergoing total pancreatectomy followed by
autologous islet transplantation: a case report.”
B.L. Bartlett, D. Chujo, T. Itoh, S. Iwahashi, M.F.
Levy, S. Matsumoto, B. Naziruddin, N. Onaca,
M. Shimoda, M. Takita, Y. Tamura. Pancreas.
42(1):175-177. 2013.
“Beta cell function after islet transplantation.”
In “Type 1 Diabetes.” M.F. Levy, B. Naziruddin,
S. Nigar, M. Takita. Editors: A.P. Escher, A.
Li. InTech. Rijeka, Croatia. 167-194. 2013.
“CD11b(+) cells in donor-specific transfusion
prolonged allogenic skin graft survival through
indoleamine 2,3-dioxygenase.” T. Ikemoto, M.F.
Levy, B. Naziruddin, M. Shimada, M. Takita.
Cell Immunol. 283(1-2): 81-90. 2013.
Temple SJ, Kim PT, Serrano PE, Kagedan
D, Cleary SP, Moulton CA, McGilvray ID,
Gallinger S, Greig PD, Wei AC. Combined
pancreaticoduodenectomy and colon resection for
locally advanced peri-ampullary tumours: analysis
of peri-operative morbidity and mortality. HPB
(Oxford); 2014 Sep;16(9):797-800.
“Changes in metabolic profiles after the
Great East Japan Earthquake: a retrospective
observational study.” T. Hamaki,
Lee JJ, Kim PT, Fischer S, Fung S, Gallinger S,
McGilvray I, Moulton CA, Wei AC, Greig PD,
Cleary SP. Impact of viral hepatitis on outcomes
after liver resection for hepatocellular carcinoma:
results from a North American center. Ann Surg
Oncol.; 2014 Aug;21(8):2708-16.
“Withaferin A inhibits pro-inflammatory
cytokine induced damage to islets in culture and
following transplantation.” T. Itoh, M.A. Kanak,
M.F. Levy, M.C. Lawrence, S. Matsumoto, B.
Naziruddin, H. Peng, J.A. SoRelle, K. Sugimoto.
Diabetologia. 56(4): 814-824. 2013.
K. Hara, M. Kami, K. Kobayashi, T. Matsumura,
G. Oiso, T. Okawada, H. Tachiya, M. Takita, T.
Tanimoto, M. Tsubokura. BMC Public Health.
13: 267. 2013.
“Improving allogeneic islet transplantation by
suppressing Th17 and enhancing Treg with
histone deacetylase inhibitors.” D. Chujo, T. Itoh,
M.F. Levy, S. Matsumoto, B. Naziruddin, M.
Shimada, M. Shimoda, J.A. Sorelle, K. Sugimoto,
M. Takita. Transplant International. 27(4): 408415. 2014.
“Inflammatory Response in Islet
Transplantation.” M.A. Kanak, F. Kunnathodi,
M.C. Lawrence, M.F. Levy, M. Takita.
International Journal of Endocrinology. 2014:
451035. 2014.
“Islet Product Characteristics and Factors Related
to Successful Human Islet Transplantation
from the Collaborative Islet Transplant Registry
(CITR) 1999-2010.”
R. Alejandro, A.N. Balamurugan, F.B. Barton, T.
Berney, B.J. Hering, T.W.H. Kay, J. Kerr-Conti,
T. Kin, C. Liu, A. Lockridge, G. Loganathan, P.
Maffi, J. Markmann, S. Messinger, S. Matsumoto,
B. Naziruddin, P.J. O’Connell, K. Papas, A.
Posselt, M.R. Rickels, C. Ricordi, A. Secchi,
M. Takita, M. Tiwari, M. Trieger, S. Wease,
P. Witkowski, X. Zhang. American Journal of
Transplantation. 14(11): 2595-2606. 2014.
“Pancreatic ductal perfusion at organ
procurement enhances islet yield in human islet
isolation.” T. Itoh, M.A. Kanak, F. Kunnathodi,
M.C. Lawrence, M.F. Levy, B. Naziruddin, R.
Shahbazov, M. Shimoda, M. Takita. Pancreas.
43(8): 1249-1255. 2014.
“Total pancreatectomy with islet
autotransplantation: summary of a national
institute of diabetes and digestive and kidney
diseases workshop.” D.K. Andersen, G. ArreazaRubin, M.D. Bellin, T.B. Dunn, A. Gelrud,
A. Humar, K.A. Morgan, B. Naziruddin, C.
Rastellini, M.R. Rickels, S.J. Schwarzenberg.
Pancreas. 43(8): 1163-1171. 2014.
P U B L I C ATI O NS
2013 Heart and Lung Publications
“Aortic valve and ascending aorta guidelines for
management and quality measures: executive
summary.” D.A. Adams, C.W. Akins, J.
Bavaria, E.H. Blackstone, R.O. Bonow, T.E.
David, R. D’Agostino, T. Dewey, T. Gleason,
K.B. Harrington, S. Kapadia, S. Kodali, N.
Kouchoukos, M. Leon, B. Lima, B. Lytle, M.J.
Mack, D.C. Miller, P.T. O’Gara, B. Reece, G.R.
Reiss, E.E. Roselli, H. Schaff, D. Shahian, C.R.
Smith, L.G. Svensson, V. Thourani, M. Tuzcu, J.
Webb, M.R. Williams. The Annals of Thoracic
Surgery. 95(4): 1491-505. 2013.
“Bioprosthetic aortic valve changes late after
insertion of a left ventricular assist device.” G.V.
Gonzalez-Stawinski, K. Khvilivitzky. Baylor
University Medical Center Proceedings. 26(1):
45-6. January 2013.
“Case series using the ROTAFLOW system as
a temporary right ventricular assist device after
HeartMate II implantation.” T. Chamogeorgakis,
G.V. Gonzalez-Stawinski, M. Hanna, A. KhaniHanjani, G. Loor, M. Mountis, A. Shafii, E.
Soltesz. ASAIO Journal. 59(4): 456-60. JulyAugust 2013.
“Chylopericardium Following Orthotopic Lung
Transplantation.” J.E. Capehart, B.W. Hardaway,
M.A. Ramsay, R.L. Rosenblatt, M.A. Wait.
Baylor University Medical Center Proceedings.
26(3): 280-2. July 2013.
“Combined heart and liver transplantation: the
Cleveland Clinic experience.” T. Chamogeorgakis,
J. Fung, G.V. Gonzalez-Stawinski, M. Hanna,
C.M. Miller, D. Nagpal, A.E. Shafii. The Annals
of Thoracic Surgery. 95(1): 179-82. January
2013.
“Dramatically different phenotypic expressions
of hypertrophic cardiomyopathy in male cousins
undergoing cardiac transplantation with identical
disease-causing gene mutation.” E. Capehart, P.A.
Grayburn, S.A. Hall, J.M. Ko, J.J. Kuiper, W.C.
Roberts, C.C. Roberts, A. Tandon. American
Journal of Cardiology. 111(12): 1818-22. June
2013.
“Effect of postoperative course on midterm
outcome after esophageal resection for cancer.”
F. Bhora, T. Chamogeorgakis, C. Connery,
A. Nabong, I. Toumpoulis. Baylor University
Medical Center Proceedings. 26(3): 239-42. July
2013.
“HLA and MICA allosensitization patterns
among patients supported by ventricular assist
devices.” M. Askar, S. Bakdash, W. Baldwin, J.
Daghstani, G.V. Gonzalez-Stawinski, E. Hsich,
L. Klingman, N. Moazami, A.S. Nowacki, P.
Reville, N. Smedira, R.C. Starling, D.O. Taylor,
A. Zhang. The Journal of Heart and Lung
Transplantation. 32(12): 1241-8. December
2013.
“Impact of nutritional state on lung transplant
outcomes.” E.H. Blackstone, T. Chamogeorgakis,
D.P. Mason, S.C. Murthy, G.B. Pettersson, D.P.
Raymond, L. Thuita. The Journal of Heart and
Lung Transplantation. 32(7): 693-700. July 2013.
“Modifications, classification, and outcomes of
elephant-trunk procedures.” L.H. Batizy, E.H.
Blackstone, A.M. Gillinov, B.W. Lytle, A.E.
Rafael, E.E. Roselli, G.D. Rushing, J.F. Sabik, III,
L.G. Svensson, E.S. Valenzuela. The Annals of
Thoracic Surgery. 96(2): 548-58. August 2013.
33
“The myth of the Bernheim syndrome.” T.
Chamogeorgakis, M.S. Chung, S.A. Hall, J.M.
Ko, W.C. Roberts. Baylor University Medical
Center Proceedings. 26(4): 401-4. October 2013.
“Outcomes of axillary artery side graft
cannulation for extracorporeal membrane
oxygenation.” T. Chamogeorgakis, G.V.
Gonzalez-Stawinski, B. Lima, D. Mason, D.
Nagpal, J.L. Navia, J.A. Pokersnik, A.E. Shafii.
The Journal of Thoracic and Cardiovascular
Surgery. 145(4): 1088-92. April 2013.
“Pathologic correlates of heparin-free donation
after cardiac death in lung transplantation.” C.R.
Brown, C.F. Farver, D.P. Mason, S.C. Murthy,
G.B. Pettersson, A.E. Shafii. The Journal of
Thoracic and Cardiovascular Surgery. 145(5):
e49-50. May 2013.
“Timing of heparin and thrombus formation
in donor lungs after cardiac death.” C.R.
Brown, C.F. Farver, H.B. Keshava, D.P. Mason,
S.C. Murthy, G.B. Pettersson, A.E. Shafii, N.
Vakil, J.J. Yun. The Journal of Thoracic and
Cardiovascular Surgery. 61(3): 246-50. April
2013.
“Which is better: a miniaturized percutaneous
ventricular assist device or extracorporeal
membrane oxygenation for patients with
cardiogenic shock?” T. Chamogeorgakis, G.V.
Gonzalez-Stawinski, D. Nagpal, J.A. Pokersnik,
A. Rafael, A.E. Shafii. ASAIO Journal. 59(6):
607-11. November-December 2013.
2014 Heart and Lung Publications
“Anomalous cord from the raphe of a congenitally
bicuspid aortic valve to the aortic wall producing
either acute or chronic aortic regurgitation.” G.V.
Gonzalez-Stawinski, J.M. Ko, G.D. Trachiotis,
B.J. Roberts, C.S. Roberts, W.C. Roberts, T.J.
Vowels. Journal of the American College of
Cardiology. 63(2): 153-7. Jan. 21, 2014.
“Bilateral Diaphragmatic Paralysis Associated
with the Use of the Tumor Necrosis Factor-Alpha
Inhibitor Adalimumab.” M. Benjamin, M.D.;
A.W. Martin, M.D.; R. L. Rosenblatt, M.D.
Baylor University Medical Center Proceedings.
27(2): 113-115. April 2014.
“Cardiac Restriction Secondary to Massive
Calcific Deposits in the Left Ventricular Cavity.”
P. A. Grayburn, M.D.; J.M. Guileyardo, M.D.;
J.M. Ko, B.A.; J.J. Kuiper, M.D.; W.C. Roberts,
M.D.; R.L. Rosenblatt, M.D. The American
Journal of Cardiology. 15. 113(8): 1442-1448.
April 2014.
“Expanding the Donor Pool: Donation after
Cardiac Death.” H. Elgharably, D.P. Mason, A.E.
Shafii. In-press, Thoracic Surgery Clinics.
“Fat in the ventricular septum.” T.
Chamogeorgakis, E.E. Donaldson, J.M. Ko, J.J.
Kuiper, W.C. Roberts. Baylor University Medical
Center Proceedings. 27(3): 231-2. July 2014.
“Increased need for right ventricular support
in patients with chemotherapy-induced
cardiomyopathy undergoing mechanical
circulatory support: outcomes from the
INTERMACS Registry (Interagency Registry for
Mechanically Assisted Circulatory Support).” M.
Dupont, G.V. Gonzalez-Stawinski, S.L. Myers,
D. Naftel, G.H. Oliveira, R.C. Starling, W.H.
Tang, D.O. Taylor, J.B. Young, Y. Yuan. Journal
of the American College of Cardiology. 63(3):
240-8. Jan. 28, 2014.
“Intracardiac abscess with cutaneous fistula
secondary to ventricular septal defect repair
simulating sternal wound infection.” S.
Keshavamurthy, C.C. Miranda, T. Okamoto, G.B.
Pettersson, A.E. Rafael, E. Sepulveda. Texas Heart
Institute Journal. 41(3): 324-6. June 1, 2014.
“Microsporidiosis Acquired Through Solid Organ
Transplantation: A Public Health Investigation.”
M. de Almeida, Ph.D; S. Antony, M.D.; T.
Benedict, B.S.; D.M. Blau, D.V.M., Ph.D; I.
Castillo, R.N., B.S.N.; H. Diaz-Luna, M.D.;
G.C. Friedman, M.D.; C.S. Goldsmith, M.G.S.;
S.N. Hocevar, M.D.; M.J. Kuehnert, M.D.; S.
Luna, R.N.; C.D. Paddock, M.D.; T. Peterson,
R.N., M.S.N./M.P.H., C.P.T.C.; R. Rosenblatt,
M.D.; A. da Silva, Ph.D; C.W. Spak, M.D.; R.R.
Sriram, B.S.; R.A. Stoddard, D.V.M., Ph.D; R.V.
Tiller, M.P.H.; G.S. Visvesvara, Ph.D; S.R. Zaki,
M.D., Ph.D; for the Microsporidia Transplant
Transmission Investigation Team. Annals of Internal
Medicine. 160(4): 213-220. Feb. 18 2014.
“Morphologic features of cardiac sarcoidosis
in native hearts of patients having cardiac
transplantation.” J.E. Capehart, M.S. Chung, S.A.
Hall, J.M. Ko, W.C. Roberts. American Journal of
Cardiology. 113(4): 706-712. Feb. 15, 2014.
“Morphologic features of the recipient heart
in patients having cardiac transplantation and
analysis of the congruence or incongruence
between the clinical and morphologic diagnosis.”
Roberts WC, Roberts CC, Ko JM, Filardo G,
Capehart JE, and Hall SA. Medicine. July 2014;
93(5):211-235.
“Secondary Arrhythmogenic Right Ventricular
Cardiomyopathy Decades After Operative Repair
of Tetralogy of Fallot.” E.E. Donaldson, G.V.
Gonzalez-Stawinski, S.A. Hall, J.M. Ko, W.C.
Roberts. American Journal of Cardiology. pii:
S0002-9149(14)01273-9. June 18, 2014.
“Spectroscopic limb monitoring in peripheral
extracorporeal membrane oxygenation.” S.
Keshavamurthy, A.E. Shafii, E. Soltesz. Asian
Cardiovascular and Thoracic Annals. June 6, 2014.
“Surgical repair of postoperative lymphoceles in
cardiac transplant patients following inguinal
lymphangiography with methylene blue dye
injection.” T.J. Chamogeorgakis, P.A. Compton,
M.A. Cura, J.D. Sacks. Journal of Vascular and
Interventional Radiology. 25(4): 656-8. April 2014.
“Too High for Transplantation? Single-Center
Analysis of the Lung Allocation Score.” E.
Blackstone, C. Brown, M. Budev, D. Mason, S.
Murthy, G. Pettersson, A.E. Shafii, L. Thuita. Inpress, The Annals of Thoracic Surgery.
“Treatment of Left Ventricular Assist Device–
Associated Arteriovenous Malformations with
Thalidomide.” R. Ha, P.P. Kale, R. Ray. ASAIO
Journal. 60(4): 482-483. July/August 2014.
“Utility of cardiac computed tomography
for inflow cannula patency assessment and
prediction of clinical outcome in patients with
the HeartMateII left ventricular assist device.”
J. Sacks, MD, G. Gonzalez-Stawinski, MD, S.
Hall, MD, W. Dockery, MD, M. Cura, MD,
B. Lima, MD, and T. Chamogeorgakis, MD..
Jnl of Cardiovascular Computed Tomography.
(submitted 2014).
33
MEDICAL S TA F F
Abdominal Transplant Surgeons
Göran B. Klintmalm, MD, PhD, FACS
Chairman and Chief, Baylor Simmons Transplant Institute;
Vice Chair, Department of Surgery;
Division Chief, Transplant Surgery
Robert M. Goldstein, MD, FACS
Assistant Director, Transplant Surgery;
Surgical Director, Hepatobiliary Surgery;
Director, LPC
Marlon F. Levy, MD, FACS
Surgical Director, Baylor All Saints
Transplant Program;
Medical Director, Pancreas, Islet Cell Program
Giuliano Testa, MD, FACS, MBA
Surgical Director, Living Donor Liver Transplantation
Tiffany Anthony, MD
Director, Laparoscopic Donor Nephrectomy
Peter Tae Wan Kim MD, MSc, FRCS(C)
Assistant Director, Living Donor Liver
Transplantation
Gregory J. McKenna, MD, FRCS(C), FACS
Director, Liver Transplant Surgical Research
Nicholas Onaca, MD
Surgical Director, Kidney Transplantation
Richard M. Ruiz, MD, FACS
Director, Pancreas Transplantation;
Director, Transplant Fellowship Program
Heart Transplant Surgeons
Gonzalo Gonzalez-Stawinski, MD
Chief of Heart Transplantation and Mechanical Circulatory
Support and Chief of Cardiac Services for
Baylor Dallas
Themistokles Chamogeorgakis, MD
Associate Director of Heart Transplantation & Mechanical
Circulatory Support;
Medical Director of Quality for CV Surgical Services
Brian Lima, MD
Director of Clinical Research, Heart Transplantation and
Mechanical Circulatory Support
Juan MacHannaford, MD
Vice Chairman of CV Surgical Services
Aldo Rafael, MD
Lung Transplant Surgeons
David P. Mason, MD
Chief of Thoracic Surgery and Lung Transplantation, Baylor
Scott and White
Alexis Shafii, MD
Associate Director of Lung Transplantation;
Director of ECMO
Aldo Rafael, MD
Themistokles Chamogeorgakis, MD
Cardiologists
Shelley A. Hall, MD, FACC
Chief of Transplant Cardiology and Mechanical Circulatory
Support/Heart Failure
34
Johannes J. Kuiper, MD
Director, Outreach and Shared Care
Jose Mendez, MD
Amarinda Bindra, MD
Parag Kale, MD
Adnan Khalid, MD
Hepatologists
James Trotter, MD
Program Director for General and Transplant Hepatology
BHCS
Natalie G. B. Murray, MD
Medical Director Liver Transplant, BASMC
Jacqueline O’Leary, MD, MPH
Medical Director of Hepatology Research and Liver Unit
Mohammad Ashfaq, MD
Sumeet Asrani, MD, MSC
Manjushree Gautam, MD, MAS
Stevan A. Gonzalez, MD, MS
Linsheng Guo, MD
Carmen Landaverde, MD
Maria Lepe, MD
Director, Hepatology Fellowship Program
Apurva A. Modi, MD
Robert Perrillo, MD
Robert S. Rahimi, MD, MSCR
Jennifer T. Wells, MD
Nephrologists
Bernard V. Fischbach, MD
Medical Director of Renal and Pancreas Transplantation
Steven Hays, MD
Medical Director, Living Donor Kidney Program
Yousri Barri, MD
Arun Chandrakantan, MD
Larry Melton, MD
Imran Memon, MD
Patrick Nef, MD
Arthi Rajagopal, MD
Kim Rice, MD
Angelito Yango, MD
Pulmonologists
Randall L. Rosenblatt, MD, MACP, FACCP
Chief of Pulmonary and Critical Care Medicine;
Medical Director, Lung Transplantation
Howard J Huang, MD
Assistant Medical Director, Lung Transplantation
Kenneth Ausloos, MD
Medical Director, Interstitial Lung Disease and Pulmonary
Hypertension
Mark Millard, MD
Medical Director, Martha Foster Lung Center
M E D I C AL STA F F
Heart Team
Shelley Hall, MD; Johannes Kuiper, MD;
Juan MacHannaford, MD; Aldo Rafael, MD;
Gonzalo Gonzalez-Stawinski, MD; Themistokles
Chamogeorgakis, MD
Not pictured: Brian Lima, MD; Amarinda Bindra,
MD; Parag Kale, MD; Adnan Khalid, MD; Jose
Mendez, MD
Hepatology Team
Back row L to R: James Trotter, MD; Linsheng
Guo, MD; Apurva A. Modi, MD; Jennifer Wells, MD;
Mohammed Ashfaq, MD; Carmen Landaverde, MD;
Stevan A. Gonzalez, MD, MS; Robert Rahimi, MD.
Front row L to R: Manjushree Gautam, MD, MAS;
Jacqueline O’Leary, MD, MPH; Sumeet Asrani, MD;
Natalie G.B. Murray, MD; Rita Lepe-Suastegui, MD
Not pictured: Robert Perrillo, MD
Lung Team
Kenneth Ausloos, MD; David Mason, MD;
Alexis Shafii, MD; Randall Rosenblatt, MD;
Howard Huang, MD
Not pictured: Themistokles Chamogeorgakis, MD;
Aldo Rafael, MD
Abdominal Transplant Surgery Team
L to R: Peter Kim, MD; Nicholas Onaca, MD; Tiffany
Anthony, MD; Robert M. Goldstein, MD, FACS; Richard
Ruiz, MD, FACS; Göran B. Klintmalm, MD, PhD, FACS;
Gregory J. McKenna, MD; Giuliano Testa, MD, FACS,
MBA; Marlon F. Levy, MD, FACS
35
35
B AY L O R
FIRSTS
NORTH TEXAS’ FIRST islet cell transplant
T R A N S P L A N TS
MA K E L I F E
WORTH LIVING
We receive countless comments from our
family of more than 11,000 patients about
NATION’S FIRST certified VAD program
life after transplant. Comments such as:
“Thanks to the liver I received, I was
SOUTHWEST’S FIRST adult liver transplant
able to pass my knowledge to a new
generation of physicists.”
WORLD’S FIRST extra-corporeal perfusion (bridge
to transplant) using a genetically engineered pig
“I married my beautiful wife, and a few
liver, keeping the patient alive before successfully
years later we adopted our son.”
undergoing liver transplantation
“I had to put school on hold while
NORTH TEXAS’ FIRST split-liver procedure:
my chronic kidney disease progressed.
a donor liver was divided into two lobes for a
I graduated with my MBA this past
pediatric and an adult recipient
Friday!”
NORTH TEXAS’ FIRST adult-to-adult living donor
“Dancing with my daughter was a
liver transplant procedure
pleasure we would not have had without
a donor and willing family, the Baylor
NORTH TEXAS’ FIRST heart/lung/heart “domino”
transplant team and the grace of God.”
procedure: a patient with terminal emphysema
received a heart and two lungs, while a patient with
For all the milestones our transplant program
cardiomyopathy received the good heart from the
has achieved, the greatest are those celebrated
emphysema patient
by our patients. Their stories remind us
that as transplantation changes lives it
NORTH TEXAS’ FIRST paired kidney
changes history. After 30 years of pioneering
donor transplant
transplants, we are honored to reflect on the
miracles in generations of lives that our work
NORTH TEXAS’ FIRST and only living liver
donor program
36
has made possible.
Cancer research studies on the campus of Baylor University Medical Center at Dallas and Baylor All Saints Medical Center at Fort Worth are conducted through Baylor Research
Institute, Texas Oncology and US Oncology. Each reviews, approves and conducts clinical trials independently. Their clinical trials are listed together in this publication for the
convenience of patients and physicians.
Physicians provide clinical services as members of the medical staff at one of Baylor Scott & White Health’s subsidiary, community or affiliated medical centers and do not provide
clinical services as employees or agents of those medical centers, Baylor Health Care System, Scott & White Healthcare or Baylor Scott & White Health. Individual results may vary.
Not all services available at all locations. ©2015 Baylor Scott & White Health.
For our patients—who continually
amaze us with their perseverance.
For our donors—who gave the
ultimate gift, the possibility of life.
For our physicians and staff—who
help make it all happen.
Baylor Annette C. and Harold C. Simmons Transplant Institute is the integration of transplant
services at Baylor University Medical Center at Dallas and Baylor All Saints Medical Center at
Fort Worth. Together, Baylor Dallas and Baylor Fort Worth are one of the largest multispecialty
transplant centers in the country.
1.800.774.2487 BaylorHealth.com/Transplant